Specialty Pharmacy

Teplizumab is a humanized IgG1κ Fc-nonbinding anti-CD3 monoclonal antibody that blocks T cells, preventing them from attacking beta cells.

The allogeneic CAR-T cell therapy is in development for relapsed or refractory large B cell lymphoma and relapsed or refractory B cell non-Hodgkin lymphoma.

With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.

Treatment with immune checkpoint inhibitors have the potential for immune-related adverse events, such as psoriasis.

Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma.

Pharmacists can coordinate education programs for patients to normalize quality of life and minimize infusion-related pain.

The trial data demonstrated that pembrolizumab in combination with chemotherapy also had statistically significant and clinically meaningful improvements in PFS and ORR as well.

Pharmacists should engage patients, explore system fixes to prevent missed drug-drug interactions

The adeno-associated virus vector-based gene therapy is the first gene therapy to be approved by the FDA for hemophilia B.

IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules.

Stock shelves with boutique and unique products to anchor existing customer, attract new ones.

Pharmacists can coordinate educational programs for patients to normalize quality of life and minimize infusion-related pain.

Changes in DNA methylation may lead to accelerated aging in patients with cancer and HIV.

Complete due diligence before selecting a compounding pharmacy and establishing an outsourcing relationship.

Guselkumab (Tremfya) is a fully human selective IL-23 inhibitor therapy FDA-approved for the treatment of adults with active psoriatic arthritis and with moderate to severe plaque psoriasis.

Generic small molecule drugs take advantage of abbreviated approval pathways and have markedly lower development costs compared to their reference products.

When it comes to individualized treatment, “we can do better,” said John Edwards, vice president of Healthcare Solutions Consulting at SoftServe.

The goals of therapy for atopic dermatitis include reducing symptoms of pruritis and dermatitis with disease control and prevention of flares.

PrEP reduces the risk of getting HIV from sex by about 99% for certain patient population with consistent adherence.

Analysis indicates that a 25-mg dose reduces the condition scores significantly more than a 1mg dose over a 3-week period, but the 10-mg dose did not yield the same results.

Intravenous immunoglobulin is used for several autoimmune and inflammatory conditions, although researchers have not fully understood its specific mechanisms.

Cerebral adrenoleukodystrophy is a progressive neurodegenerative disease causes irreversible neurologic decline and can result in functional disabilities, such hearing loss and cortical blindness.

Poster presentations and speaking sessions at NASP showed the importance of clinical pharmacists in ambulatory care and opportunities to expand specialty pharmacy services in ambulatory care.

Leaders must fully understand the benefits of diversity and create an environment in which it thrives to cultivate and inspire the next generation of inclusive leaders.

A session presenter at the ASCP 2022 Annual Meeting addresses research investigating the value of preventative treatments when patients have a limited life expectancy.

Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody.

Promising data suggest triplet regimens may more effectively treat patients with unresected and metastatic intrahepatic cholangiocarcinoma.

Pharmacists are the premier medication experts within health care, who understand more about medication interactions than most physicians and have the unique ability to prevent complications, improve adherence, and save lives.

Teprotumumab is the first fully human IgG1 monoclonal antibody approved by the FDA for the treatment of thyroid eye disease at its source not just reducing the symptoms.

ART also results in a faster decay of plasma HIV RNA and increased HIV CD8+T cell immunity compared with the treatment alone, investigators found.